Table 1: Sample characteristics

Age (M/SD)

74.25 (6.08)^b

71.82 (7.45)^a,c

74.17 (8.37)^b

Gender (male/female))

115/106

244/170

38/35

Education (M/SD)

16.36 (2.73)^c

16.14 (2.74)^c

15.18 (3.06)^a,b

Follow-up in years (M/SD)

4.89 (2.5)^b,c

4.24 (1.81)^a,c

2.15 (0.44)^a,b

ApoE4-status (pos./neg.)

55/166

203/211

60/13

ApoE-alleles (22/23/33/24/34/44)

0/30/136/1/50/4

0/28/183/6/148/49

0/0/13/2/36/22

Amyloid-status (pos./neg.)

72/148

245/169

73/0

CSF-Aβ_1–42 (M/SD)

1243.25 (421.93)^b,c

976.67 (444.52)^a,c

545.03 (159.15)=

CSF-p-tau₁₈₁ (M/SD)

21.97 (9.24)^b,c

27.55 (14.27)^a,c

36.77 (14.33)^a,b

CSF sTREM2 (M/SD)

4258.60 (2183.71)

4094.56 (2104.86)

4370.51 (2194.07)

ADNI-MEM (M/SD)

1.07 (0.58)^b,c

0.23 (0.67)^a,c

−0.84 (0.50)^a,b

ADAS13 (M/SD)

9.08 (4.33)^b,c

15.80 (6.61)^a,c

28.82 (6.88)^a,b

MMSE (M/SD)

29.11 (1.14)^b,c

27.80 (1.78)^a,c

23.12 (1.89)^a,b